title: Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
abstract: Curcumin (diferuloylmethane) is a phenolic compound present in turmeric and is ingested daily in many parts of the world. Curcumin has been reported to cause inhibition on proliferation and induction of apoptosis in many human cancer cell lines, including non-small cell lung cancer cells (NSCLC). However, the clinical application of curcumin is restricted by its low bioavailability. In this report, it was observed that combined treatment of a low dosage of curcumin (5-10 µM) with a low concentration (0.1-2.5 µM) of small molecule inhibitors, including AG1478, AG1024, PD173074, LY294002 and caffeic acid phenethyl ester (CAPE) increased the growth inhibition in two human NSCLC cell lines: A549 and H1299 cells. The observation suggested that combined treatment of a low dosage of curcumin with inhibitors against epidermal growth factor receptor (EGFR), insulin-like growth factor 1 (IGF-1R), fibroblast growth factors receptor (FGFR), phosphatidylinositol 3-kinases (PI3K) or NF-κB signaling pathway may be a potential adjuvant therapy beneficial to NSCLC patients.
authors.affiliation: Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli County, Taiwan.
authors.forename: Hui-Ping
authors.initials: HP
authors.lastname: Lin
authors.forename: Li-Kuo
authors.initials: LK
authors.lastname: Kuo
authors.forename: Chih-Pin
authors.initials: CP
authors.lastname: Chuu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D002109:Caffeic Acids / Q000494:pharmacology / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology / Q000627:therapeutic use; D030024:Curcuma / Q000737:chemistry*; D003474:Curcumin / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000081082:Phosphoinositide-3 Kinase Inhibitors; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D013002:Somatomedins / Q000037:antagonists & inhibitors; D020032:Tyrphostins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D002109:Caffeic Acids; D002867:Chromones; D004791:Enzyme Inhibitors; D009025:Morpholines; D016328:NF-kappa B; C115711:PD 173074; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010936:Plant Extracts; D011743:Pyrimidines; D011799:Quinazolines; D017468:Receptors, Fibroblast Growth Factor; D013002:Somatomedins; D020032:Tyrphostins; C447031:tyrphostin AG 1024; C101044:RTKI cpd; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D066246:ErbB Receptors; C055494:caffeic acid phenethyl ester; D003474:Curcumin; D010626:Phenylethyl Alcohol